Evidence map›Paper›PMID 40995828›Full record

ArticleThe Cochrane database of systematic reviews2025

Once- or twice-daily thoracic radiation in limited-stage small-cell lung cancer treated with concurrent chemoradiotherapy.

Ken Harada, Kazuya Inoki, Takenori Ichimura, Kanae Taruno, Hidenori Shinjo, Noyuri Yamaji, Hisashi Noma, Erika Ota, Takeshi Hasegawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ken HaradaDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID 0000-0002-9859-6871
Kazuya InokiDivision of Gastroenterology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Takenori IchimuraDepartment of Hospital Pharmaceutics, Showa Medical University, Tokyo, Japan.
Kanae TarunoDivision of Breast Surgical Oncology, Department of Surgery, Showa Medical University School of Medicine, Tokyo, Japan.
Hidenori ShinjoDivision of Radiation Oncology, Department of Radiology, Graduate School of Medicine, Showa Medical University, Tokyo, Japan.
Noyuri YamajiInstitute of Clinical Epidemiology, Showa Medical University, Tokyo, Japan.
Hisashi NomaInstitute of Clinical Epidemiology, Showa Medical University, Tokyo, Japan.
Erika OtaInstitute of Clinical Epidemiology, Showa Medical University, Tokyo, Japan.
Takeshi HasegawaInstitute of Clinical Epidemiology, Showa Medical University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of once-daily radiotherapy versus twice-daily radiotherapy concurrently with chemotherapy for optimal survival outcomes in people with limited-stage small-cell lung cancer (LS-SCLC).

Indexed as

ChemoradiotherapyLung NeoplasmsSmall Cell Lung CarcinomaHumansRandomized Controlled Trials as TopicSystematic Reviews as Topic

Identifiers

PMID40995828
PMCPMC12461785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.